Uncertainty over President Trump's new tariff policies almost knocked stocks into a bear market a year ago. While growth stocks suffered the most, value stocks also declined. Even bond prices were lower amid the confusion. Stocks have since recovered and the bull market that began in 2022 remains intact. But inflation is still an issue and now the Federal Reserve's treasured and valuable independence may be in question. Is a correction in the offing, given the high level of stock prices? Taking into account all the variables, is it time for investors to cash in their chips? As the market fluctuates between bull and bear, we note that investors exit equities at their own peril. So what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate.

Johnson & Johnson is a diversified global healthcare company that develops, manufactures, and markets products in two business segments: Innovative Medicine (formerly Pharmaceuticals) and MedTech.

The major U.S. stock indices are mixed at midday on Friday, with the S&P 500 and Nasdaq higher while the Dow Jones Industrial Average and Russell 2000 are lower. The split results mirror a volatile week, with stock initially falling hard on headlines and then popping back on new headlines that made the originals drop into the 'never mind' category. Driving the action today are results from Intel that badly disappointed and consumer sentiment data that improved a tad but remains lower based on historical trends.

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.